Merifin Capital
VC Fund
Brussels, Belgium
Merifin Capital is an experienced European private investment group with offices and executives operating in:Brussels Geneva New York LondonMerifin Capital has successfully invested in traditional and alternative asset classes for a period of over twenty years. At the present time, Merifin Capital and its affiliates manage a substantialinvestment portfolio and maintain an active investment program.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Merifin Capital invests in
BiotechnologyTherapeuticsManufacturingMedicalElectronics
Stages Merifin Capital invests in
Series ASeries CSeries DSeries BSeries E
Countries Merifin Capital invests in
United StatesGermanyUnited KingdomItalyFrance
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Coen Teulings
|
|||
|
Guillaume de Rham
|
|||
|
Jan Huysmans
|
|||
|
Theo Stokman
|
|||
Christopher Wright
|
Investment Focus
Industry
- Biotechnology 4 (33%)
- Therapeutics 3 (25%)
- Manufacturing 3 (25%)
- Medical 2 (17%)
- Electronics 2 (17%)
Stage
- Series A 3 (25%)
- Series C 2 (17%)
- Series D 2 (17%)
- Series B 1 (8%)
- Series E 1 (8%)
Country
- United States 3 (25%)
- Germany 2 (17%)
- United Kingdom 2 (17%)
- Italy 1 (8%)
- France 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Coen Teulings
Chairman
|
Chairman | Total investments: 0 | Find email | |
|
Guillaume de Rham
Director
|
Director | Total investments: 0 | Find email | |
|
Jan Huysmans
Director
|
Director | Total investments: 0 | Find email | |
|
Theo Stokman
Director
|
Director | Total investments: 0 | Find email | |
|
Christopher Wright
Director
|
Director | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
F2G
|
F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversifiedinto chemistry-driven discovery. They have also assembled an experienced development capacity. | Private Equity / Jun 20, 2016 | |
DoveConviene
|
DoveConviene S.R.L. designs and develops a digital platform which helps people to shop by saving money through offers and leaflets presented georeferenced manner. The company was founded in 2010 and is based in Sestu, Italy.The startup trades under the brand DoveConviene in Italy and ShopFully in the U.S., as well as various other names inSpain, Brazil, Mexico and Indonesia (TechCrunch). | $11M / Series C / Sep 25, 2015 | |
|
DoveConviene
|
DoveConviene S.R.L. designs and develops a digital platform which helps people to shop by saving money through offers and leaflets presented georeferenced manner. The company was founded in 2010 and is based in Sestu, Italy.The startup trades under the brand DoveConviene in Italy and ShopFully in the U.S., as well as various other names inSpain, Brazil, Mexico and Indonesia (TechCrunch). | $5.7M / Series B / Dec 03, 2014 | |
Flayr
|
Launched in 2013 in France, Flayr is a unique place for shopping discoveries, allowing people to discover outsourced and crowdsourced edgy little brands and take benefit of great deals on big brands. Flayr is very user-centric, designed only to fulfill their users' every needs.Flayr is developped in Paris, Caen (yes, Caen, Normandy-basedcity somewhere in France is the new Palo Alto) & USA by Olivier, Nicolas, Philippe, Jerome, Pierre, Delphine, Clémence, Arnaud, Valentin, Jérôme, Antoine, Antoine, Julie, Nabil, Tiphaine, Guillaume, Julien, Isaline, Romain, David, Cassio, and Arthur.France finally found its fourth F: "Fashion, Fragrance, Fromage and Flayr"! | $6.1M / Series A / Nov 20, 2013 | |
|
F2G
|
F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversifiedinto chemistry-driven discovery. They have also assembled an experienced development capacity. | $30M / Sep 05, 2012 | |
|
F2G
|
F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversifiedinto chemistry-driven discovery. They have also assembled an experienced development capacity. | $8M / Aug 18, 2008 | |
Plastic Logic Germany
|
Plastic Logic Germany leads the way in developing, manufacturing and commercializing flexible displays. The company has successfully industrialized the manufacturing process in its facility, the world’s first commercial, volume, organic electronics factory. Using a stable and proven licensed technology transistor platform, the company manufacturesa range of high-quality, flexible plastic displays. These shatterproof, daylight-readable displays are ultra-thin, ultra-lightweight and very low-power, offering huge advantages over conventional screens as they are extremely robust with proven lifetimes. Plastic Logic Germany also runs an open pilot line for flexible electronics. Third party companies are invited to benefit from the company’s years of experience in the industrialization and manufacture of flexible electronics. Plastic Logic Germany’s customers include OEMs and electronics manufacturers for signage and logistics, mobile electronic devices, smart-cards, wearables and more.For more information, please visit www.plasticlogic.com. | $100M / Series D / Jan 06, 2007 | |
|
Metara
|
Metara manufactures chemical metrology tools for semiconductor industry that are used in monitoring and controlling chemical processes. Its products include sentry trace contamination metrology system, which monitors benign chemistries for trace contaminants; and sentry chemical composition metrology system, which monitors copper electroplating andcobalt bath chemistries. The company also offers sentry harsh chemistry metrology system, an analysis solution for harsh chemistries used in semiconductor manufacturing processes; and inline mass spectrometer, a chemical metrology solution that determines chemical composition and potential yield-or process-limiting contaminants. Metara Inc. was founded in 2000 and is headquartered in Sunnyvale, California. | $11.5M / Series E / Nov 15, 2005 | |
DanioLabs
|
DanioLabs Ltd. discovers and develops therapeutics for neurological, ophthalmologic, metabolic, and gastrointestinal diseases. | $4.2M / Series A / Jan 17, 2005 | |
immatics biotechnologies
|
immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy. immatics has a good track record of success: They are optimistic that they have found a way to develop drugs against cancer that might one day help many cancer patients. The product candidates are designed to have less severeside effects than currently available treatment options. immatics has developed peptide-based active immunotherapy with unprecedented speed and efficiency, setting new standards for discovery and development in this area of oncology drug development. Our technology can also lead towards the development of novel immunotherapies based on antibodies and T-cell receptors. immatics is currently working on the development of new substances for a number of specific cancer types. Their most advanced product is currently being developed in a phase 3 clinical trial for kidney cancer. Final results for this trial are expected in 2015. A second product targeting colorectal cancer has just completed a large phase 1/2 clinical trial and a third cancer vaccine has entered several phase 1 clinical trials in brain cancer. They also have active earlier programs in several other tumor types including gastric cancer, non-small-cell lung cancer and prostate cancer which are being developed in collaboration with our partner Roche. | $8.6M / Series A / Feb 11, 2004 | |
| See all 12 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
Health Care Investors
43,014 investors
Climate Investors
40,325 investors
Hardware Investors
40,144 investors
Consumer Investors
32,380 investors
Manufacturing Investors
24,696 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Health Care VC Funds
32,370 investors
FAQ
What does Merifin Capital invest in?
Merifin Capital invests primarily in Biotechnology, Therapeutics and Manufacturing startups, most often at Series A and Series C stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Merifin Capital?
Public channels for Merifin Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Merifin Capital?
The team at Merifin Capital includes Coen Teulings (Chairman), Guillaume de Rham (Director) and Jan Huysmans (Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
